For professionals
About us
Support we offer
About the diseases
Get involved
Blog
More
The impact you'll make | The Big Give Christmas Challenge 2023
NICE approves life-saving treatment for children with infantile lysosomal acid lipase deficiency
SMC do not recommend pegunigalsidase alfa (Elfabrio®) for adult Fabry patients
NICE approves life-changing medication for treatment of alpha mannosidosis
NICE approves its first ERT for treating Fabry disease
Bob's rare disease road trip
TOGETHER WE CAN TRANSFORM LIVES
NICE unfortunately leans towards a ‘no’ for the treatment of early onset LAL D (Wolman disease)
Robert's story | MPS Awareness Week 2023
MPS Society Strategy 2023-2026
Impact report 2022
BBC documentary highlights the importance of Newborn Screening for early diagnosis
Celebrating 40 years
NICE leans towards a no for the treatment of Alpha Mannosidosis
Footsteps Dance School raises funds in honour of Isaac Turner
MPS Society celebrates after receiving £10,000 in National Lottery funding
Takeda to discontinue their TAK-609 clinical trial
NICE approves life-changing medication for treating MPS IVA Morquio
NICE final guidance approves life-changing gene therapy for treating MLD
NICE update on the re-evaluation for the treatment of MPS IVA (Morquio A)
AVROBIO ends its gene therapy trial for Fabry disease
NICE leans towards a no for the treatment of MPS IVA (Morquio A)
Will changes to NICE processes work for rare diseases?
MPS Society’s Group CEO elected to the ABPI’s new Patient Advisory Council
COVID-19 vaccination for children and young people aged 12-17 years
NICE unfortunately leans towards a no for the treatment of Metachromatic Leukodystrophy (MLD).
MPS 2021 International Symposium
Vimizim update from NICE for MPS IVA (Morquio)
New COHERE study for MPS II patients
MPS Society's chance to win £1,000
What's new for Sophie?
We welcome Mandy who has started a brand new role at the MPS Society
Conference 2021 Announcement
National Lottery Community Fund award £195K to build connections and reduce feelings of isolation
MPS Society welcomes new UK Rare Diseases Framework
Treatment for Metachromatic Leukodystrophy (MLD) approved by the European Commission
Latest information for clinically extremely vulnerable adults and children
Kelly Mills' charity appeal for MPS Society on Radio 4
AVROBIO announce collaborative research agreement with Manchester university for MPS II gene therapy
REGENXBIO announces expansion of gene therapy programme for the treatment of MPS II
Tune in to Kelly Mills' charity appeal for MPS Society on Radio 4 this month
Ross Kemp's Living With Dementia series visits a family affected by Sanfilippo
Impact report 2019/20
Brain disease treatment shows promising signs
NHS England and shielding (updated 24 June 2020)
Paediatric advice on clinical support and homecare (updated 26 March)
Changes to our service as a result of COVID-19
MPS Society response to Budget announcement
Advice for patients, parents and guardians on inherited metabolic disease and Coronavirus (COVID-19)